Cytochrome P450 3A4 activity and genetic variants as predictors of liver failure in patients with obstructive jaundice
Liver failure in patients with obstructive jaundice is a significant contributor to mortality within this patient cohort. The exact mechanism and triggers of this occurrence are yet to be fully understood. With this in mind, our study aimed to assess the correlation between the urinary 6 β-OHC/C rat...
Saved in:
| Published in | Free radical biology & medicine Vol. 208; pp. 229 - 235 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.11.2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0891-5849 1873-4596 1873-4596 |
| DOI | 10.1016/j.freeradbiomed.2023.08.012 |
Cover
| Abstract | Liver failure in patients with obstructive jaundice is a significant contributor to mortality within this patient cohort. The exact mechanism and triggers of this occurrence are yet to be fully understood. With this in mind, our study aimed to assess the correlation between the urinary 6 β-OHC/C ratio and various biochemical parameters of liver function. Furthermore, we conducted genotyping of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746) polymorphic markers to investigate the potential effects of their variants on the probability of liver failure in obstructive jaundice. Our study included 75 patients diagnosed with severe obstructive jaundice. All test subjects underwent functional liver tests, and control blood tests were administered on the seventh day following biliary decompression. Patients were categorized into two groups: group 1 - patients without liver failure (n = 60) and group 2 - patients with liver failure (n = 15). Laboratory indexes such as 6 β –OHC concentration and 6 β- OHC/cortisol ratio can serve as significant predictors of liver failure in patients with moderate and severe degree obstructive jaundice after biliary decompression. Based on the study of “wild” and polymorphic variants of CYP3A4*22 (CC and CT) and polymorphism of CYP3A5*3A6986G (GG, GA, AA), it was discovered that liver failure in the CYP3A4*22 variant may be associated with the CC genotype, and in the CYP3A5*3 variant - with the GA genotype. Hence, the determination of 6β- OHC concentration and 6β- OHC/C ratio, as well as the analysis of polymorphic and “wild” variants of CYP3A4*22 (CC and CT) and CYP3A5*3 polymorphism A6986G (GG, GA, AA), may play a crucial role in predicting liver failure in patients with obstructive jaundice.
[Display omitted]
•Decrease in activity of CYP3A in patients with obstructive jaundice can lead to liver failure.•Determination of 6β- OHC concentration and 6β- OHC/C ratio may be used for prediction of liver failure.•Study of polymorphic and “wild” variants of CYP3A4*22 (CC and CT) and CYP3A5*3 polymorphism A6986G (GG, GA, AA) is important in patients with obstructive jaundice. |
|---|---|
| AbstractList | Liver failure in patients with obstructive jaundice is a significant contributor to mortality within this patient cohort. The exact mechanism and triggers of this occurrence are yet to be fully understood. With this in mind, our study aimed to assess the correlation between the urinary 6 β-OHC/C ratio and various biochemical parameters of liver function. Furthermore, we conducted genotyping of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746) polymorphic markers to investigate the potential effects of their variants on the probability of liver failure in obstructive jaundice. Our study included 75 patients diagnosed with severe obstructive jaundice. All test subjects underwent functional liver tests, and control blood tests were administered on the seventh day following biliary decompression. Patients were categorized into two groups: group 1 - patients without liver failure (n = 60) and group 2 - patients with liver failure (n = 15). Laboratory indexes such as 6 β -OHC concentration and 6 β- OHC/cortisol ratio can serve as significant predictors of liver failure in patients with moderate and severe degree obstructive jaundice after biliary decompression. Based on the study of "wild" and polymorphic variants of CYP3A4*22 (CC and CT) and polymorphism of CYP3A5*3A6986G (GG, GA, AA), it was discovered that liver failure in the CYP3A4*22 variant may be associated with the CC genotype, and in the CYP3A5*3 variant - with the GA genotype. Hence, the determination of 6β- OHC concentration and 6β- OHC/C ratio, as well as the analysis of polymorphic and "wild" variants of CYP3A4*22 (CC and CT) and CYP3A5*3 polymorphism A6986G (GG, GA, AA), may play a crucial role in predicting liver failure in patients with obstructive jaundice. Liver failure in patients with obstructive jaundice is a significant contributor to mortality within this patient cohort. The exact mechanism and triggers of this occurrence are yet to be fully understood. With this in mind, our study aimed to assess the correlation between the urinary 6 β-OHC/C ratio and various biochemical parameters of liver function. Furthermore, we conducted genotyping of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746) polymorphic markers to investigate the potential effects of their variants on the probability of liver failure in obstructive jaundice. Our study included 75 patients diagnosed with severe obstructive jaundice. All test subjects underwent functional liver tests, and control blood tests were administered on the seventh day following biliary decompression. Patients were categorized into two groups: group 1 - patients without liver failure (n = 60) and group 2 - patients with liver failure (n = 15). Laboratory indexes such as 6 β -OHC concentration and 6 β- OHC/cortisol ratio can serve as significant predictors of liver failure in patients with moderate and severe degree obstructive jaundice after biliary decompression. Based on the study of "wild" and polymorphic variants of CYP3A4*22 (CC and CT) and polymorphism of CYP3A5*3A6986G (GG, GA, AA), it was discovered that liver failure in the CYP3A4*22 variant may be associated with the CC genotype, and in the CYP3A5*3 variant - with the GA genotype. Hence, the determination of 6β- OHC concentration and 6β- OHC/C ratio, as well as the analysis of polymorphic and "wild" variants of CYP3A4*22 (CC and CT) and CYP3A5*3 polymorphism A6986G (GG, GA, AA), may play a crucial role in predicting liver failure in patients with obstructive jaundice.Liver failure in patients with obstructive jaundice is a significant contributor to mortality within this patient cohort. The exact mechanism and triggers of this occurrence are yet to be fully understood. With this in mind, our study aimed to assess the correlation between the urinary 6 β-OHC/C ratio and various biochemical parameters of liver function. Furthermore, we conducted genotyping of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746) polymorphic markers to investigate the potential effects of their variants on the probability of liver failure in obstructive jaundice. Our study included 75 patients diagnosed with severe obstructive jaundice. All test subjects underwent functional liver tests, and control blood tests were administered on the seventh day following biliary decompression. Patients were categorized into two groups: group 1 - patients without liver failure (n = 60) and group 2 - patients with liver failure (n = 15). Laboratory indexes such as 6 β -OHC concentration and 6 β- OHC/cortisol ratio can serve as significant predictors of liver failure in patients with moderate and severe degree obstructive jaundice after biliary decompression. Based on the study of "wild" and polymorphic variants of CYP3A4*22 (CC and CT) and polymorphism of CYP3A5*3A6986G (GG, GA, AA), it was discovered that liver failure in the CYP3A4*22 variant may be associated with the CC genotype, and in the CYP3A5*3 variant - with the GA genotype. Hence, the determination of 6β- OHC concentration and 6β- OHC/C ratio, as well as the analysis of polymorphic and "wild" variants of CYP3A4*22 (CC and CT) and CYP3A5*3 polymorphism A6986G (GG, GA, AA), may play a crucial role in predicting liver failure in patients with obstructive jaundice. Liver failure in patients with obstructive jaundice is a significant contributor to mortality within this patient cohort. The exact mechanism and triggers of this occurrence are yet to be fully understood. With this in mind, our study aimed to assess the correlation between the urinary 6 β-OHC/C ratio and various biochemical parameters of liver function. Furthermore, we conducted genotyping of CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746) polymorphic markers to investigate the potential effects of their variants on the probability of liver failure in obstructive jaundice. Our study included 75 patients diagnosed with severe obstructive jaundice. All test subjects underwent functional liver tests, and control blood tests were administered on the seventh day following biliary decompression. Patients were categorized into two groups: group 1 - patients without liver failure (n = 60) and group 2 - patients with liver failure (n = 15). Laboratory indexes such as 6 β –OHC concentration and 6 β- OHC/cortisol ratio can serve as significant predictors of liver failure in patients with moderate and severe degree obstructive jaundice after biliary decompression. Based on the study of “wild” and polymorphic variants of CYP3A4*22 (CC and CT) and polymorphism of CYP3A5*3A6986G (GG, GA, AA), it was discovered that liver failure in the CYP3A4*22 variant may be associated with the CC genotype, and in the CYP3A5*3 variant - with the GA genotype. Hence, the determination of 6β- OHC concentration and 6β- OHC/C ratio, as well as the analysis of polymorphic and “wild” variants of CYP3A4*22 (CC and CT) and CYP3A5*3 polymorphism A6986G (GG, GA, AA), may play a crucial role in predicting liver failure in patients with obstructive jaundice. [Display omitted] •Decrease in activity of CYP3A in patients with obstructive jaundice can lead to liver failure.•Determination of 6β- OHC concentration and 6β- OHC/C ratio may be used for prediction of liver failure.•Study of polymorphic and “wild” variants of CYP3A4*22 (CC and CT) and CYP3A5*3 polymorphism A6986G (GG, GA, AA) is important in patients with obstructive jaundice. |
| Author | Bochkov, Pavel O. Tavobilov, Mikhail M. Shabunin, Alexey V. Lebedev, Sergey S. Abramov, Kirill A. Karpov, Alexey A. Denisenko, Natalia P. Sychev, Dmitri A. Shevchenko, Roman V. |
| Author_xml | – sequence: 1 givenname: Sergey S. surname: Lebedev fullname: Lebedev, Sergey S. organization: Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, st. Barrikadnaya, 2/1, Russia – sequence: 2 givenname: Mikhail M. surname: Tavobilov fullname: Tavobilov, Mikhail M. organization: Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, st. Barrikadnaya, 2/1, Russia – sequence: 3 givenname: Alexey A. surname: Karpov fullname: Karpov, Alexey A. organization: Botkin Hospital, Russian Academy of Sciences, Moscow, st. 2nd Botkinsky proezd, 5, Russia – sequence: 4 givenname: Kirill A. orcidid: 0000-0001-9871-114X surname: Abramov fullname: Abramov, Kirill A. email: botkin.abramov@gmail.com organization: Botkin Hospital, Russian Academy of Sciences, Moscow, st. 2nd Botkinsky proezd, 5, Russia – sequence: 5 givenname: Pavel O. surname: Bochkov fullname: Bochkov, Pavel O. organization: Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, st. Barrikadnaya, 2/1, Russia – sequence: 6 givenname: Roman V. surname: Shevchenko fullname: Shevchenko, Roman V. organization: Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, st. Barrikadnaya, 2/1, Russia – sequence: 7 givenname: Natalia P. surname: Denisenko fullname: Denisenko, Natalia P. organization: Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, st. Barrikadnaya, 2/1, Russia – sequence: 8 givenname: Alexey V. surname: Shabunin fullname: Shabunin, Alexey V. organization: Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, st. Barrikadnaya, 2/1, Russia – sequence: 9 givenname: Dmitri A. surname: Sychev fullname: Sychev, Dmitri A. organization: Russian Medical Academy of Continuing Professional Education, Ministry of Health of the Russian Federation, Moscow, st. Barrikadnaya, 2/1, Russia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37573895$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc-L1DAYhoOsuLOr_4IEvHhp_ZI0bYqnZVh_wIIe9BzS5KubodOMSVqZ_96UWQVvnnL4nveFPO8NuZrDjIS8YVAzYO27Qz1GxGjc4MMRXc2BixpUDYw_IzumOlE1sm-vyA5Uzyqpmv6a3KR0AIBGCvWCXItOdkL1ckfW_TkH-xhLE_3aSKDirqHGZr_6fKZmdvQHzpi9pauJ3sw5UZPoKaLzNoeYaBjp5FeMdDR-WiJSP9OTyR439JfPjzQMKcdlq0R6MMtckviSPB_NlPDV03tLvn-4_7b_VD18-fh5f_dQWcFlrgS4lgEYZnjbO2nF2DZiNNz1gg-DhB6hca21kikFrFdODKZcoeuBNxt1S95eek8x_FwwZX30yeI0mRnDkjRXEjom21YU9PUTugxFqz5FfzTxrP-4KsD7C2BjSCni-BdhoLdl9EH_s4zeltGgdFmmpO8vaSzfXT1GnWyRZIvIiDZrF_x_9fwG9-Sejw |
| Cites_doi | 10.1080/00498254.2019.1648911 10.1046/j.0306-5251.2001.01545.x 10.1038/tpj.2010.28 10.1038/85417 10.1097/FPC.0000000000000183 10.1038/86882 10.1097/00008571-200007000-00001 10.1146/annurev.pharmtox.38.1.389 10.1038/clpt.1992.3 10.1016/j.pharmthera.2012.12.007 10.1038/clpt.1992.140 10.1002/(SICI)1097-0142(19960415)77:8<1427::AID-CNCR2>3.0.CO;2-9 10.1038/clpt.2014.129 10.1177/0091270002042012012 10.1016/S0009-9236(99)70029-9 10.1124/dmd.31.11.1283 10.1016/j.phrs.2005.02.014 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier Inc. Copyright © 2023. Published by Elsevier Inc. Copyright © 2023 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2023 Elsevier Inc. – notice: Copyright © 2023. Published by Elsevier Inc. – notice: Copyright © 2023 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.freeradbiomed.2023.08.012 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology |
| EISSN | 1873-4596 |
| EndPage | 235 |
| ExternalDocumentID | 37573895 10_1016_j_freeradbiomed_2023_08_012 S0891584923005841 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M -~X .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABLJU ABLVK ABMAC ABMZM ABUDA ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV C45 CS3 DOVZS DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KOM LCYCR LX3 LZ2 M29 M41 MO0 N9A O-L O9- OAUVE OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K TEORI ~G- .GJ .HR 29H 53G AAQXK AATTM AAXKI AAYWO AAYXX ABWVN ABXDB ACIEU ACRPL ACVFH ADCNI ADMUD ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGHFR AGQPQ AGRDE AGRNS AHHHB AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB G-2 HEA HLW HMK HMO HVGLF HX~ HZ~ R2- SBG WUQ XPP ZGI NPM 7X8 ACLOT EFKBS ~HD |
| ID | FETCH-LOGICAL-c325t-30d6100a1a269d5c3f643fa2d932bb509e04d6cc51880198d3baa2d0790242d93 |
| IEDL.DBID | AIKHN |
| ISSN | 0891-5849 1873-4596 |
| IngestDate | Sun Sep 28 08:09:54 EDT 2025 Thu Apr 03 07:09:25 EDT 2025 Tue Jul 01 01:11:48 EDT 2025 Sat Mar 02 16:00:30 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Obstructive jaundice CYP3A4 cytochrome activity |
| Language | English |
| License | Copyright © 2023. Published by Elsevier Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c325t-30d6100a1a269d5c3f643fa2d932bb509e04d6cc51880198d3baa2d0790242d93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-9871-114X |
| PMID | 37573895 |
| PQID | 2850715663 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2850715663 pubmed_primary_37573895 crossref_primary_10_1016_j_freeradbiomed_2023_08_012 elsevier_sciencedirect_doi_10_1016_j_freeradbiomed_2023_08_012 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-11-01 |
| PublicationDateYYYYMMDD | 2023-11-01 |
| PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Free radical biology & medicine |
| PublicationTitleAlternate | Free Radic Biol Med |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Kinirons, O'Shea, Kim, Groopman, Thummel, Wood, Wilkinson (bib8) 1999; 66 Werk, Cascorbi (bib15) 2014; 96 Watkins, Turgeon, Saenger, Lown, Kolars, Hamilton, Fishman, Guzelian, Voorhees (bib7) 1992; 52 Saima, Furuie, Yoshimoto, Fukuda, Hayashi, Echizen (bib10) 2002; 53 Ng, Young, Critchley, Leung, Lau, Li (bib13) 1996; 77 Kuehl, Zhang, Lin, Lamba, Assem, Schuetz, Watkins, Daly, Wrighton, Hall, Maurel, Relling, Brimer, Yasuda, Venkataramanan, Strom, Thummel, Boguski, Schuetz (bib19) 2001; 27 EL Desoky, Mohamed, Farghaly, Hamed, Hedaya, Siest (bib12) 2005; 51 Furuta, Suzuki, Mori, Shibasaki, Yokokawa, Kasuya (bib2) 2003; 31 Wang, Sadee (bib16) 2016 Jan; 26 Uejima, Takahashi, Morisaki, Takahashi, Ohno, Nishida, Moriya, Kaido, Abe, Sakoda (bib11) 2002; 42 Thummel, Shen, Podoll (bib9) 1994; 271 Thummel, Wilkinson (bib4) 1998; 38 Ozdemir, Kalown, Tang, Paterson, Walter, Endrenyi, Kashuba (bib5) 2000; 10 Eichelbaum, Burk (bib1) 2001; 7 Shimada, Yamazaki, Mimura, Inui, Guengerich (bib3) 1994; 270 Wang, Guo, Wrighton, Cooke, Sadee (bib17) 2011; 11 Hunt, Watkins, Saenger, Stave, Barlascini, Watlington, Wright, Guzelian (bib6) 1992; 51 Zanger, Schwab (bib18) 2013; 138 Waring (bib14) 2020; 50 Shimada (10.1016/j.freeradbiomed.2023.08.012_bib3) 1994; 270 Werk (10.1016/j.freeradbiomed.2023.08.012_bib15) 2014; 96 Uejima (10.1016/j.freeradbiomed.2023.08.012_bib11) 2002; 42 Ozdemir (10.1016/j.freeradbiomed.2023.08.012_bib5) 2000; 10 Thummel (10.1016/j.freeradbiomed.2023.08.012_bib9) 1994; 271 EL Desoky (10.1016/j.freeradbiomed.2023.08.012_bib12) 2005; 51 Wang (10.1016/j.freeradbiomed.2023.08.012_bib17) 2011; 11 Kuehl (10.1016/j.freeradbiomed.2023.08.012_bib19) 2001; 27 Watkins (10.1016/j.freeradbiomed.2023.08.012_bib7) 1992; 52 Zanger (10.1016/j.freeradbiomed.2023.08.012_bib18) 2013; 138 Saima (10.1016/j.freeradbiomed.2023.08.012_bib10) 2002; 53 Thummel (10.1016/j.freeradbiomed.2023.08.012_bib4) 1998; 38 Ng (10.1016/j.freeradbiomed.2023.08.012_bib13) 1996; 77 Furuta (10.1016/j.freeradbiomed.2023.08.012_bib2) 2003; 31 Kinirons (10.1016/j.freeradbiomed.2023.08.012_bib8) 1999; 66 Waring (10.1016/j.freeradbiomed.2023.08.012_bib14) 2020; 50 Hunt (10.1016/j.freeradbiomed.2023.08.012_bib6) 1992; 51 Eichelbaum (10.1016/j.freeradbiomed.2023.08.012_bib1) 2001; 7 Wang (10.1016/j.freeradbiomed.2023.08.012_bib16) 2016; 26 |
| References_xml | – volume: 38 start-page: 389 year: 1998 end-page: 430 ident: bib4 article-title: In vitro and in vivo drug interactions involving human CYP3A publication-title: Annu. Rev. Pharmacol. Toxicol. – volume: 138 start-page: 103 year: 2013 end-page: 141 ident: bib18 article-title: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation publication-title: Pharmacol. Ther. – volume: 52 start-page: 265 year: 1992 end-page: 273 ident: bib7 article-title: Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity publication-title: Clin. Pharmacol. Ther. – volume: 26 start-page: 40 year: 2016 Jan end-page: 43 ident: bib16 article-title: CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing publication-title: Pharmacogenetics Genom. – volume: 42 start-page: 1374 year: 2002 end-page: 1379 ident: bib11 article-title: Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity publication-title: J. Clin. Pharmacol. – volume: 270 start-page: 414 year: 1994 end-page: 423 ident: bib3 article-title: Interindividual variations in human CYP 450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians publication-title: J. Pharmacol. Exp. Therapeut. – volume: 50 start-page: 9 year: 2020 end-page: 18 ident: bib14 article-title: Cytochrome P450: genotype to phenotype publication-title: Xenobiotica – volume: 7 start-page: 285 year: 2001 end-page: 287 ident: bib1 article-title: CYP3A genetics in drug metabolism publication-title: Nat. Med. – volume: 53 year: 2002 ident: bib10 article-title: The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects publication-title: Br. J. Clin. Pharmacol. – volume: 10 start-page: 373 year: 2000 end-page: 388 ident: bib5 article-title: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method publication-title: Pharmacogenetics – volume: 51 start-page: 18 year: 1992 end-page: 23 ident: bib6 article-title: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol publication-title: Clin. Pharmacol. Ther. – volume: 96 start-page: 340 year: 2014 end-page: 348 ident: bib15 article-title: Functional gene variants of CYP3A4 publication-title: Clin. Pharmacol. Ther. – volume: 66 start-page: 224 year: 1999 end-page: 231 ident: bib8 article-title: Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A publication-title: Clin. Pharmacol. Ther. – volume: 51 start-page: 575 year: 2005 end-page: 580 ident: bib12 article-title: Study of urinary 6β- hydroxycortisol/cortisol ratio in spot urine samples as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population publication-title: Pharmacol. Res. – volume: 77 start-page: 1427 year: 1996 end-page: 1433 ident: bib13 article-title: Urinary 6β-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases publication-title: Cancer – volume: 27 year: 2001 ident: bib19 article-title: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression publication-title: Nat. Genet. – volume: 31 start-page: 1283 year: 2003 end-page: 1287 ident: bib2 article-title: Evidence for the validity of cortisol 6 β-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans publication-title: Drug Metabol. Dispos. – volume: 271 start-page: 557 year: 1994 end-page: 566 ident: bib9 article-title: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of interand intraindividual hepatic CYP3A variability after liver transplantation publication-title: J. Pharmacol. Exp. Therapeut. – volume: 11 start-page: 274 year: 2011 end-page: 286 ident: bib17 article-title: Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs publication-title: Pharmacogenomics J. – volume: 271 start-page: 557 year: 1994 ident: 10.1016/j.freeradbiomed.2023.08.012_bib9 article-title: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of interand intraindividual hepatic CYP3A variability after liver transplantation publication-title: J. Pharmacol. Exp. Therapeut. – volume: 50 start-page: 9 issue: 1 year: 2020 ident: 10.1016/j.freeradbiomed.2023.08.012_bib14 article-title: Cytochrome P450: genotype to phenotype publication-title: Xenobiotica doi: 10.1080/00498254.2019.1648911 – volume: 53 year: 2002 ident: 10.1016/j.freeradbiomed.2023.08.012_bib10 article-title: The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects publication-title: Br. J. Clin. Pharmacol. doi: 10.1046/j.0306-5251.2001.01545.x – volume: 11 start-page: 274 year: 2011 ident: 10.1016/j.freeradbiomed.2023.08.012_bib17 article-title: Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs publication-title: Pharmacogenomics J. doi: 10.1038/tpj.2010.28 – volume: 7 start-page: 285 year: 2001 ident: 10.1016/j.freeradbiomed.2023.08.012_bib1 article-title: CYP3A genetics in drug metabolism publication-title: Nat. Med. doi: 10.1038/85417 – volume: 26 start-page: 40 issue: 1 year: 2016 ident: 10.1016/j.freeradbiomed.2023.08.012_bib16 article-title: CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing publication-title: Pharmacogenetics Genom. doi: 10.1097/FPC.0000000000000183 – volume: 27 issue: 4 year: 2001 ident: 10.1016/j.freeradbiomed.2023.08.012_bib19 article-title: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression publication-title: Nat. Genet. doi: 10.1038/86882 – volume: 10 start-page: 373 year: 2000 ident: 10.1016/j.freeradbiomed.2023.08.012_bib5 article-title: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method publication-title: Pharmacogenetics doi: 10.1097/00008571-200007000-00001 – volume: 38 start-page: 389 year: 1998 ident: 10.1016/j.freeradbiomed.2023.08.012_bib4 article-title: In vitro and in vivo drug interactions involving human CYP3A publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pharmtox.38.1.389 – volume: 51 start-page: 18 year: 1992 ident: 10.1016/j.freeradbiomed.2023.08.012_bib6 article-title: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.1992.3 – volume: 138 start-page: 103 year: 2013 ident: 10.1016/j.freeradbiomed.2023.08.012_bib18 article-title: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2012.12.007 – volume: 52 start-page: 265 year: 1992 ident: 10.1016/j.freeradbiomed.2023.08.012_bib7 article-title: Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.1992.140 – volume: 77 start-page: 1427 year: 1996 ident: 10.1016/j.freeradbiomed.2023.08.012_bib13 article-title: Urinary 6β-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19960415)77:8<1427::AID-CNCR2>3.0.CO;2-9 – volume: 96 start-page: 340 year: 2014 ident: 10.1016/j.freeradbiomed.2023.08.012_bib15 article-title: Functional gene variants of CYP3A4 publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2014.129 – volume: 42 start-page: 1374 year: 2002 ident: 10.1016/j.freeradbiomed.2023.08.012_bib11 article-title: Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity publication-title: J. Clin. Pharmacol. doi: 10.1177/0091270002042012012 – volume: 270 start-page: 414 year: 1994 ident: 10.1016/j.freeradbiomed.2023.08.012_bib3 article-title: Interindividual variations in human CYP 450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians publication-title: J. Pharmacol. Exp. Therapeut. – volume: 66 start-page: 224 year: 1999 ident: 10.1016/j.freeradbiomed.2023.08.012_bib8 article-title: Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A publication-title: Clin. Pharmacol. Ther. doi: 10.1016/S0009-9236(99)70029-9 – volume: 31 start-page: 1283 year: 2003 ident: 10.1016/j.freeradbiomed.2023.08.012_bib2 article-title: Evidence for the validity of cortisol 6 β-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans publication-title: Drug Metabol. Dispos. doi: 10.1124/dmd.31.11.1283 – volume: 51 start-page: 575 year: 2005 ident: 10.1016/j.freeradbiomed.2023.08.012_bib12 article-title: Study of urinary 6β- hydroxycortisol/cortisol ratio in spot urine samples as a biomarker of 3A4 enzyme activity in healthy and epileptic subjects of Egyptian population publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2005.02.014 |
| SSID | ssj0004538 |
| Score | 2.4424605 |
| Snippet | Liver failure in patients with obstructive jaundice is a significant contributor to mortality within this patient cohort. The exact mechanism and triggers of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 229 |
| SubjectTerms | CYP3A4 cytochrome activity Obstructive jaundice |
| Title | Cytochrome P450 3A4 activity and genetic variants as predictors of liver failure in patients with obstructive jaundice |
| URI | https://dx.doi.org/10.1016/j.freeradbiomed.2023.08.012 https://www.ncbi.nlm.nih.gov/pubmed/37573895 https://www.proquest.com/docview/2850715663 |
| Volume | 208 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VrUBcUGl5LIVqEIhbuokdJ_Gl0mpFtYCokKBSb5YdO2IrSFbd7Up74bczkwe0h0pIHJPYieWZeD57Hh_A2zT43AmvI1_qKkqFzSInsziqJPvcSu8zy8nJn8-y-Xn68UJd7MBsyIXhsMp-7e_W9Ha17u9M-tmcLBeLyde40AmZT0IozI3Hyeu7gqx9MYLd6YdP87MbRcNbQmtuH3GHB_Dmb5hXdRUCe63bZPdjJhNvS3om4i5DdRcQbQ3S6R486pEkTrvBPoadUO_DwbSmXfTPLb7DNrazPTTfh_sd5eT2ADaz7bopv3ORAvySqhjlNEVObmAOCbS1R9IoTmzEDe2iOUgG7QqXV-zPYWIebCr8wbEcWNkFh7Tjosa-OOsK-VQXG9cXpd0EvLTXNfUMT-D89P232TzquReiUgq1jmTsCVjFNrEi016VsiLoUlmSqhTOEcoIceqzsmzruSW68NJZehrnmo0-tXoKo7qpw3PAIqik8loVVsepDJl1ylmXOSdlroNIx5AOE22WXYkNM8SeXZpb8jEsH8O8mYkYw8kgFHNLYwwZg397wetBlIb-KXaU2Do01ysjCkbJBHTlGJ51Mv4zMpmrnECeevG_nz-Eh3zV5TW-hBFJJrwigLN2R3Dv-Fdy1Kvxb6rh_JI |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7Chra5lDRpm-1zSktv7tp62NalsCwNmyZZCk0gNyFZMt2Q2Et2s7D_vho_muYQKPRqSbbQjDWfNI8P4JPwLrPMqcgVqowEM2lkeRpHJSefW-Fcaig5-XSWTs_F9wt5sQWTPheGwiq7vb_d05vdunsy6lZztJjPRz_jXCXBfAaEQtx4lLy-LYjUegDb46Pj6eyvouENoTX1j2jAY_h4F-ZV3nhPXusm2f0LkYk3JT0T9pChegiINgbpcBeedkgSx-1kn8GWr_Zgf1yFU_T1Bj9jE9vZXJrvwaOWcnKzD-vJZlUXv6hIAf4QMkY-FkjJDcQhgaZyGDSKEhtxHU7RFCSDZomLG_LnEDEP1iVeUSwHlmZOIe04r7ArzrpEutXF2nZFadceL81tFUb653B--O1sMo067oWo4EyuIh67AKxikxiWKicLXgboUpogVc6sDSjDx8KlRdHUc0tU7rg1oTXOFBn90OsFDKq68geAuZdJ6ZTMjYoF96mx0hqbWst5pjwTQxD9QutFW2JD97Fnl_qefDTJRxNvZsKG8LUXir6nMToYg397wYdelDr8U-QoMZWvb5ea5YSSA9DlQ3jZyvjPzHgmswDy5Kv__fx7eDI9Oz3RJ0ez49ewQy1tjuMbGAQp-bcB7Kzsu06ZfwOewf54 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cytochrome+P450+3A4+activity+and+genetic+variants+as+predictors+of+liver+failure+in+patients+with+obstructive+jaundice&rft.jtitle=Free+radical+biology+%26+medicine&rft.au=Lebedev%2C+Sergey+S&rft.au=Tavobilov%2C+Mikhail+M&rft.au=Karpov%2C+Alexey+A&rft.au=Abramov%2C+Kirill+A&rft.date=2023-11-01&rft.issn=1873-4596&rft.eissn=1873-4596&rft.volume=208&rft.spage=229&rft_id=info:doi/10.1016%2Fj.freeradbiomed.2023.08.012&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0891-5849&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0891-5849&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0891-5849&client=summon |